US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CERo Therapeutics Holdings, Inc.

1.99

-0.3800-16.03%

Post-market: 2.030.0400+2.01%19:58 EDT

Volume:428.15K

Turnover:912.51K

Market Cap:2.40M

PE:-0.06

High:2.37

Open:2.31

Low:1.93

Close:2.37

52wk High:895.40

52wk Low:1.93

Shares:1.21M

Float Shares:1.15M

Volume Ratio:0.58

T/O Rate:37.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-35.0792

EPS(LYR):-434.4641

ROE:--

ROA:-156.89%

PB:-0.23

PE(LYR):0.00

Loading ...

Overview Company News Filings

CERo Therapeutics Is Maintained at Buy by D. Boral Capital

BRIEF-CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient With Cer-1236

CERo Therapeutics Advances Clinical Trial with Second Patient Dosed in Phase 1 Study of Novel CAR-T Therapy for Acute Myeloid Leukemia

Cero Therapeutics Holdings Inc. Announces Additional Closings of Series D Preferred Stock, Raising Over $3 Million in Private Placement

Cero Therapeutics Holdings Inc. Enters New $17.5 Million Share Purchase Agreement to Extend Equity Line Program

Cero Therapeutics Regains Compliance with Nasdaq Bid Price Requirement, Avoids Delisting

Cero Therapeutics Holdings Inc. Completes Additional Closings, Issuing 938 and 2,315 Shares of Series D Preferred Stock for $750,400 and $1,852,000 Respectively

CERo Therapeutics Raised to Buy From Hold by D. Boral Capital

Cero Therapeutics Announces No Dose-Limiting Toxicities in First Patient of Phase 1 Trial for Novel Cancer Therapy CER-1236

Top Premarket Decliners

MT Newswires Live

Top Midday Gainers

MT Newswires Live

Cero Therapeutics Holdings Inc. Receives FDA Orphan Drug Designation for CER-1236 in Acute Myeloid Leukemia Treatment

Cero Therapeutics Receives Nasdaq Delisting Notice Due to Bid Price Non-Compliance; Implements Reverse Stock Split to Address Issue

Cero Therapeutics Announces 1-for-20 Reverse Stock Split Effective June 13, 2025

Cero Therapeutics Holdings Inc. Announces Exercise of Option for Additional Series D Financing to Support Clinical Advancements

Cero Therapeutics Holdings Inc. Appoints Chris Ehrlich as New CEO with Revised Employment Agreement

Cero Therapeutics Holdings Inc. Expands IP Portfolio with New U.S. and European Patent Approvals for Lead Compound CER-1236

BRIEF-CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial

CERo Therapeutics Cut to Hold From Buy by D. Boral Capital

Cero Therapeutics Holdings Inc. Conducted Annual Stockholders Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CERO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CERO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CERO\",,,,,undefined,":{"symbol":"CERO","market":"US","secType":"STK","nameCN":"CERo Therapeutics Holdings, Inc.","latestPrice":1.99,"timestamp":1760731200000,"preClose":2.37,"halted":0,"volume":428152,"hourTrading":{"tag":"盘后","latestPrice":2.03,"preClose":1.99,"latestTime":"19:58 EDT","volume":9366,"amount":18838.771,"timestamp":1760745516344},"delay":0,"floatShares":1152545,"shares":1205400,"eps":-35.07925,"marketStatus":"Market Closed","change":-0.38,"latestTime":"10-17 16:00:00 EDT","open":2.31,"high":2.37,"low":1.93,"amount":912512.9077552,"amplitude":0.185654,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-35.07925,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":2.37,"preHourTrading":{"tag":"盘前","latestPrice":2.32,"preClose":2.37,"latestTime":"09:28 EDT","volume":9688,"amount":23262.622152,"timestamp":1760707737598},"postHourTrading":{"tag":"盘后","latestPrice":2.03,"preClose":1.99,"latestTime":"19:58 EDT","volume":9366,"amount":18838.771,"timestamp":1760745516344},"volumeRatio":0.5830397835050823},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CERO\",,,,,undefined,":{"symbol":"CERO","floatShares":1152545,"roa":"-156.89%","roe":"--","lyrEps":-434.464112,"volumeRatio":0.5830397835050823,"shares":1205400,"dividePrice":0,"high":2.37,"amplitude":0.185654,"preClose":2.37,"low":1.93,"week52Low":1.93,"pbRate":"-0.23","week52High":895.4,"institutionHeld":0,"latestPrice":1.99,"eps":-35.07925,"divideRate":0,"volume":428152,"delay":0,"ttmEps":-35.07925,"open":2.31,"prevYearClose":120,"prevWeekClose":3.31,"prevMonthClose":5.09,"prevQuarterClose":5.09,"fiveDayClose":3.31,"twentyDayClose":5.4,"sixtyDayClose":7.42},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CERO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-06-13","symbol":"CERO","defaultRemindTime":1749821400000,"type":"split","dateTimestamp":1749787200000,"forFactor":20,"toFactor":1,"ratio":20},{"market":"US","date":"2025-01-08","symbol":"CERO","defaultRemindTime":1736346600000,"type":"split","dateTimestamp":1736312400000,"forFactor":100,"toFactor":1,"ratio":100},{"market":"US","date":"2024-02-15","symbol":"CERO","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CERO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CERO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1750824000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CERO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CERO","date":"2025-10-17","current":-0.056729,"percent":0.997494,"low":-23.40166,"twenty":-5.780711,"median":-0.966838,"eighty":-0.335444,"high":-0.137942,"avg":-3.271355,"sd":4.589801,"marketCap":2856802},"quantilePoints":[{"date":"2024-02-23","current":-14.247617,"twenty":-20.956561,"median":-17.613942,"eighty":-14.944588,"marketCap":35849112},{"date":"2024-03-01","current":-17.506812,"twenty":-18.431546,"median":-15.409236,"eighty":-15.153206,"marketCap":44049729},{"date":"2024-03-08","current":-18.247371,"twenty":-17.820809,"median":-15.409236,"eighty":-15.203159,"marketCap":45913085},{"date":"2024-03-15","current":-13.270815,"twenty":-17.820809,"median":-15.409236,"eighty":-15.057448,"marketCap":33391335},{"date":"2024-03-22","current":-12.856102,"twenty":-17.518661,"median":-15.34438,"eighty":-13.839564,"marketCap":32347855},{"date":"2024-03-28","current":-9.656887,"twenty":-17.423869,"median":-15.187199,"eighty":-12.785008,"marketCap":24298158},{"date":"2024-04-05","current":-11.26226,"twenty":-17.423869,"median":-15.107401,"eighty":-12.559878,"marketCap":28563716},{"date":"2024-04-12","current":-10.85589,"twenty":-17.252059,"median":-14.262796,"eighty":-11.529063,"marketCap":27533066},{"date":"2024-04-19","current":-8.940145,"twenty":-16.820909,"median":-13.270815,"eighty":-10.646899,"marketCap":22674290},{"date":"2024-04-26","current":-8.185457,"twenty":-16.072132,"median":-12.878911,"eighty":-10.171589,"marketCap":20760226},{"date":"2024-05-03","current":-8.011298,"twenty":-15.61915,"median":-12.441389,"eighty":-9.218799,"marketCap":20318519},{"date":"2024-05-10","current":-6.676082,"twenty":-15.409236,"median":-11.944081,"eighty":-8.208678,"marketCap":16932099},{"date":"2024-05-17","current":-6.559976,"twenty":-15.406992,"median":-11.26226,"eighty":-8.011298,"marketCap":16637628},{"date":"2024-05-24","current":-5.773123,"twenty":-15.356229,"median":-10.681731,"eighty":-7.83714,"marketCap":13841623},{"date":"2024-05-31","current":-6.030941,"twenty":-15.281507,"median":-10.409864,"eighty":-6.954736,"marketCap":14459767},{"date":"2024-06-07","current":-4.748738,"twenty":-15.235078,"median":-10.159255,"eighty":-6.68061,"marketCap":11385560},{"date":"2024-06-14","current":-2.25909,"twenty":-15.107401,"median":-9.656887,"eighty":-6.509425,"marketCap":5416387},{"date":"2024-06-21","current":-1.821847,"twenty":-15.007495,"median":-8.940145,"eighty":-6.069835,"marketCap":4368054},{"date":"2024-06-28","current":-1.912311,"twenty":-14.84161,"median":-8.707933,"eighty":-5.984352,"marketCap":4584951},{"date":"2024-07-05","current":-1.595686,"twenty":-14.277975,"median":-8.24351,"eighty":-5.773123,"marketCap":3825813},{"date":"2024-07-12","current":-1.228176,"twenty":-14.247617,"median":-8.069351,"eighty":-4.748738,"marketCap":2944671},{"date":"2024-07-15","current":-1.226291,"twenty":-14.24184,"median":-8.069351,"eighty":-4.719086,"marketCap":2940152},{"date":"2024-08-02","current":-1.013952,"twenty":-14.236062,"median":-8.040325,"eighty":-4.535268,"marketCap":2431048},{"date":"2024-08-09","current":-0.885794,"twenty":-13.839564,"median":-8.011298,"eighty":-2.310102,"marketCap":2123778},{"date":"2024-08-16","current":-0.654013,"twenty":-13.158247,"median":-7.83714,"eighty":-1.891957,"marketCap":2229214},{"date":"2024-08-23","current":-2.636712,"twenty":-12.954324,"median":-7.140505,"eighty":-1.844463,"marketCap":7260829},{"date":"2024-08-30","current":-2.420589,"twenty":-12.883473,"median":-6.744599,"eighty":-1.891957,"marketCap":6665683},{"date":"2024-09-06","current":-2.068131,"twenty":-12.832404,"median":-6.687402,"eighty":-1.924373,"marketCap":5695102},{"date":"2024-09-13","current":-1.60378,"twenty":-12.678367,"median":-6.559976,"eighty":-1.829704,"marketCap":4416400},{"date":"2024-09-20","current":-1.622429,"twenty":-12.393993,"median":-6.417311,"eighty":-1.725453,"marketCap":4467754},{"date":"2024-09-27","current":-1.758564,"twenty":-12.190139,"median":-6.030941,"eighty":-1.729099,"marketCap":4842634},{"date":"2024-10-04","current":-1.723131,"twenty":-12.057464,"median":-5.826769,"eighty":-1.723525,"marketCap":4745063},{"date":"2024-10-11","current":-1.770191,"twenty":-11.67976,"median":-5.685419,"eighty":-1.725453,"marketCap":4874653},{"date":"2024-10-18","current":-1.640939,"twenty":-11.355145,"median":-5.192459,"eighty":-1.725453,"marketCap":4518726},{"date":"2024-10-25","current":-4.541316,"twenty":-11.227428,"median":-4.704227,"eighty":-1.717164,"marketCap":12505622},{"date":"2024-10-31","current":-4.448525,"twenty":-11.088102,"median":-4.448525,"eighty":-1.723131,"marketCap":12250098},{"date":"2024-11-08","current":-3.853568,"twenty":-10.85589,"median":-4.424907,"eighty":-1.725101,"marketCap":10611741},{"date":"2024-11-15","current":-10.217961,"twenty":-11.088102,"median":-4.448525,"eighty":-1.726861,"marketCap":28137649},{"date":"2024-11-22","current":-5.605162,"twenty":-11.378366,"median":-4.622772,"eighty":-1.72898,"marketCap":37261342},{"date":"2024-11-29","current":-5.285991,"twenty":-11.285481,"median":-4.70795,"eighty":-1.736236,"marketCap":29010326},{"date":"2024-12-06","current":-5.244908,"twenty":-11.122934,"median":-4.743697,"eighty":-1.739542,"marketCap":28784857},{"date":"2024-12-13","current":-1.906243,"twenty":-10.902332,"median":-4.70795,"eighty":-1.744391,"marketCap":10461755},{"date":"2024-12-20","current":-1.478982,"twenty":-10.729812,"median":-4.535858,"eighty":-1.726509,"marketCap":8116878},{"date":"2024-12-27","current":-2.097767,"twenty":-10.58386,"median":-4.43215,"eighty":-1.724313,"marketCap":11512866},{"date":"2025-01-03","current":-2.13273,"twenty":-10.499069,"median":-4.417664,"eighty":-1.725805,"marketCap":11704747},{"date":"2025-01-10","current":-1.293623,"twenty":-10.455734,"median":-4.2029,"eighty":-1.723525,"marketCap":7099600},{"date":"2025-01-17","current":-0.870573,"twenty":-10.310323,"median":-4.062655,"eighty":-1.649339,"marketCap":4777839},{"date":"2025-01-24","current":-0.821625,"twenty":-10.217961,"median":-3.965464,"eighty":-1.627827,"marketCap":4509205},{"date":"2025-01-31","current":-0.695759,"twenty":-10.19009,"median":-3.820818,"eighty":-1.596315,"marketCap":3818433},{"date":"2025-02-07","current":-0.713241,"twenty":-10.159255,"median":-2.907717,"eighty":-1.573503,"marketCap":3914374},{"date":"2025-02-14","current":-0.62933,"twenty":-10.101202,"median":-2.636712,"eighty":-1.510537,"marketCap":3453859},{"date":"2025-02-21","current":-0.716737,"twenty":-9.74575,"median":-2.540899,"eighty":-1.377788,"marketCap":3933562},{"date":"2025-02-28","current":-0.562901,"twenty":-9.640801,"median":-2.437302,"eighty":-1.224909,"marketCap":3089285},{"date":"2025-03-07","current":-0.510457,"twenty":-9.079472,"median":-2.372103,"eighty":-1.030709,"marketCap":2801464},{"date":"2025-03-14","current":-0.335713,"twenty":-8.754375,"median":-2.239137,"eighty":-0.96912,"marketCap":1842442},{"date":"2025-03-21","current":-0.335643,"twenty":-8.503123,"median":-2.198781,"eighty":-0.896348,"marketCap":1842058},{"date":"2025-03-28","current":-0.267465,"twenty":-8.285192,"median":-2.14239,"eighty":-0.857987,"marketCap":1467890},{"date":"2025-04-04","current":-0.24439,"twenty":-8.197068,"median":-2.097767,"eighty":-0.804927,"marketCap":1341248},{"date":"2025-04-11","current":-0.269213,"twenty":-8.092572,"median":-2.074831,"eighty":-0.719534,"marketCap":1477484},{"date":"2025-04-17","current":-0.137942,"twenty":-8.069351,"median":-2.037496,"eighty":-0.697857,"marketCap":1145530},{"date":"2025-04-25","current":-0.719207,"twenty":-8.034519,"median":-1.993365,"eighty":-0.682473,"marketCap":5972602},{"date":"2025-05-02","current":-0.577828,"twenty":-8.011298,"median":-1.936658,"eighty":-0.655985,"marketCap":4798528},{"date":"2025-05-09","current":-0.472927,"twenty":-8.011298,"median":-1.906243,"eighty":-0.642767,"marketCap":3927389},{"date":"2025-05-16","current":-0.378199,"twenty":-7.976467,"median":-1.862996,"eighty":-0.625834,"marketCap":3140728},{"date":"2025-05-23","current":-0.254249,"twenty":-7.883582,"median":-1.835754,"eighty":-0.593155,"marketCap":2824879},{"date":"2025-05-30","current":-0.250375,"twenty":-7.83714,"median":-1.821847,"eighty":-0.577167,"marketCap":2781833},{"date":"2025-06-06","current":-0.207274,"twenty":-7.721034,"median":-1.77581,"eighty":-0.547912,"marketCap":2302949},{"date":"2025-06-13","current":-0.273488,"twenty":-7.384327,"median":-1.751459,"eighty":-0.512702,"marketCap":3038630},{"date":"2025-06-20","current":-0.399633,"twenty":-7.094063,"median":-1.745839,"eighty":-0.507659,"marketCap":4440184},{"date":"2025-06-27","current":-0.371137,"twenty":-6.877648,"median":-1.738983,"eighty":-0.492098,"marketCap":4123580},{"date":"2025-07-03","current":-0.321791,"twenty":-6.755064,"median":-1.72792,"eighty":-0.475494,"marketCap":3575313},{"date":"2025-07-11","current":-0.307543,"twenty":-6.734135,"median":-1.723131,"eighty":-0.413641,"marketCap":3417011},{"date":"2025-07-18","current":-0.302331,"twenty":-6.698722,"median":-1.689874,"eighty":-0.38886,"marketCap":3359096},{"date":"2025-07-25","current":-0.25785,"twenty":-6.676082,"median":-1.641077,"eighty":-0.371137,"marketCap":2864884},{"date":"2025-08-01","current":-0.269665,"twenty":-6.591905,"median":-1.625128,"eighty":-0.335643,"marketCap":2996159},{"date":"2025-08-08","current":-0.28148,"twenty":-6.559976,"median":-1.603475,"eighty":-0.331869,"marketCap":3127434},{"date":"2025-08-15","current":-0.879859,"twenty":-6.509425,"median":-1.595686,"eighty":-0.331869,"marketCap":9775810},{"date":"2025-08-22","current":-0.900472,"twenty":-6.509425,"median":-1.573503,"eighty":-0.332146,"marketCap":10004836},{"date":"2025-08-29","current":-0.656668,"twenty":-6.325196,"median":-1.544714,"eighty":-0.332216,"marketCap":9245433},{"date":"2025-09-05","current":-0.593312,"twenty":-6.128686,"median":-1.49476,"eighty":-0.334162,"marketCap":8353435},{"date":"2025-09-12","current":-0.470883,"twenty":-6.040664,"median":-1.396816,"eighty":-0.335444,"marketCap":6629711},{"date":"2025-09-19","current":-0.46489,"twenty":-5.984943,"median":-1.260899,"eighty":-0.335699,"marketCap":6545332},{"date":"2025-09-26","current":-0.460609,"twenty":-5.972853,"median":-1.219381,"eighty":-0.352439,"marketCap":6485062},{"date":"2025-10-03","current":-0.461465,"twenty":-5.86852,"median":-1.092587,"eighty":-0.368234,"marketCap":6497116},{"date":"2025-10-10","current":-0.367289,"twenty":-5.817345,"median":-0.98631,"eighty":-0.370367,"marketCap":5171174},{"date":"2025-10-17","current":-0.202908,"twenty":-5.780711,"median":-0.966838,"eighty":-0.335444,"marketCap":2856802}],"updateTime":1760856165366},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CERO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2556389208","title":"CERo Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2556389208","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556389208?lang=en_us&edition=fundamental","pubTime":"2025-08-04 19:47","pubTimestamp":1754308020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CERO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 04, 2025 07:47 ET (11:47 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","LENZ"],"gpt_icon":0},{"id":"2555367508","title":"BRIEF-CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient With Cer-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2555367508","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555367508?lang=en_us&edition=fundamental","pubTime":"2025-07-31 21:45","pubTimestamp":1753969508,"startTime":"0","endTime":"0","summary":"BRIEF-CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient With Cer-1236July 31 (Reuters) - CERo Therapeutics Holdings Inc CERO.O:CERO THERAPEUTICS DOSES SECOND ACUTE MYELOID LEUKEMIA PATIENT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nTUA8MJWQK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2555376838","title":"CERo Therapeutics Advances Clinical Trial with Second Patient Dosed in Phase 1 Study of Novel CAR-T Therapy for Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2555376838","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555376838?lang=en_us&edition=fundamental","pubTime":"2025-07-31 20:10","pubTimestamp":1753963818,"startTime":"0","endTime":"0","summary":"CERo Therapeutics Advances Clinical Trial with Second Patient Dosed in Phase 1 Study of Novel CAR-T Therapy for Acute Myeloid Leukemia. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on July 31, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL81Gpty:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B775SV38.USD","IE00B3S45H60.SGD","LU1084165304.USD","IE00B64PRP62.GBP","LU0130102774.USD","LU1150488218.USD","CERO","LU0648001328.SGD","LU0203345920.USD","BK4139","LU0211328371.USD","IE00BGHQF748.EUR","LU0310799852.SGD","BK4585","LU0029864427.USD","LU1150488135.SGD","LU0211327993.USD","LU0128525929.USD","LU2210150020.SGD","SG9999014013.SGD","LU0114720955.EUR","LU2244417387.USD","LU0708994859.HKD","HCA","LU1261432733.SGD","LU0985489474.SGD","LU2210149790.SGD","LU0203347892.USD","LU2095319765.USD","SG9999014005.SGD","NDAQ","BK4185","BK4112","LU1267930573.SGD","BK4504","LU1267930490.SGD","LU0433182093.SGD","LU0868494617.USD","LU0882574055.USD","LU1119994496.HKD","IE00B3QW5Z07.USD","BK4588","SG9999014021.USD","IE00BKPKM429.USD","LU1489326972.SGD","LU1201861249.SGD","LU0310800379.SGD","SG9999014039.USD","LU0187121727.USD"],"gpt_icon":0},{"id":"2552442497","title":"Cero Therapeutics Holdings Inc. Announces Additional Closings of Series D Preferred Stock, Raising Over $3 Million in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2552442497","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552442497?lang=en_us&edition=fundamental","pubTime":"2025-07-19 04:06","pubTimestamp":1752869184,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. Announces Additional Closings of Series D Preferred Stock, Raising Over $3 Million in Private Placement. Cero Therapeutics Holdings Inc. has completed several private placement transactions involving the sale of Series D convertible preferred stock to institutional investors. On June 5, 2025, the company sold 938 shares for approximately $750,400. On June 25, 2025, an additional 2,315 shares were sold for approximately $1,852,000. Most recently, on July 18, 2025, Cero Therapeutics sold 497 shares for approximately $397,600. These transactions were conducted without registration under the Securities Act, relying on exemptions for sales to accredited investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDL79ff0Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2551185783","title":"Cero Therapeutics Holdings Inc. Enters New $17.5 Million Share Purchase Agreement to Extend Equity Line Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2551185783","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551185783?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:02","pubTimestamp":1752494529,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. has announced a new purchase agreement with an institutional investor, allowing the company to issue and sell up to $17.49 million of its common stock. This agreement, signed on July 11, 2025, continues the equity line program initiated under previous agreements in February and November 2024, which raised approximately $7.5 million through the sale of shares. The new agreement facilitates further capital infusion, subject to conditions and minus any additional proceeds from ongoing sales under the prior agreements. The commitment shares previously issued will fulfill the company's obligations, eliminating the need for additional shares as consideration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL2KRSVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2549054491","title":"Cero Therapeutics Regains Compliance with Nasdaq Bid Price Requirement, Avoids Delisting","url":"https://stock-news.laohu8.com/highlight/detail?id=2549054491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549054491?lang=en_us&edition=fundamental","pubTime":"2025-07-08 20:01","pubTimestamp":1751976094,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. recently faced a potential delisting from The Nasdaq Capital Market due to its common stock trading below the minimum required bid price of $1.00 per share for a 30-day period ending on June 9, 2025. However, after appealing the delisting decision, the company successfully regained compliance with Nasdaq's listing requirements by July 7, 2025. As a result, the planned delisting hearing was canceled, and Cero Therapeutics' stock will continue to be listed and traded on the Nasdaq Capital Market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval syst","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL92CHhT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2548487950","title":"Cero Therapeutics Holdings Inc. Completes Additional Closings, Issuing 938 and 2,315 Shares of Series D Preferred Stock for $750,400 and $1,852,000 Respectively","url":"https://stock-news.laohu8.com/highlight/detail?id=2548487950","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548487950?lang=en_us&edition=fundamental","pubTime":"2025-07-01 05:10","pubTimestamp":1751317809,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. Completes Additional Closings, Issuing 938 and 2,315 Shares of Series D Preferred Stock for $750,400 and $1,852,000 Respectively. Cero Therapeutics Holdings Inc. recently amended its securities purchase agreement, adding new institutional investors to issue and sell shares of its Series D convertible preferred stock. On June 25, 2025, the company completed an Additional Closing, selling 2,315 shares for approximately $1,852,000. Previously, on June 5, 2025, the company sold an additional 938 shares for about $750,400. The transactions were conducted under exemptions from the Securities Act for private placements to accredited investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Hol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL36Rp1r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2545443735","title":"CERo Therapeutics Raised to Buy From Hold by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2545443735","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545443735?lang=en_us&edition=fundamental","pubTime":"2025-06-23 23:16","pubTimestamp":1750691760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CERO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 23, 2025 11:16 ET (15:16 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"dbf2b98f4fe1bc6c677630a4270f9cca","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CERO"],"gpt_icon":0},{"id":"2545411954","title":"Cero Therapeutics Announces No Dose-Limiting Toxicities in First Patient of Phase 1 Trial for Novel Cancer Therapy CER-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2545411954","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545411954?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:15","pubTimestamp":1750680917,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., June 23, 2025 - CERo Therapeutics Holdings, Inc.  announced the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of its lead compound, CER-1236. The trial, titled \"Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia ,\" is designed to assess the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia. Preliminary results from the trial's Dose Escalation Safety Committee indicate that the first patient demonstrated no dose-limiting toxicity during the 28-day observation period. The company plans to dose a second patient in the cohort shortly. CERo has announced plans to initiate a second trial of CER-1236 in solid tumors later this year. Further updates on the trial's progress will be provided in the future.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDLSRJnp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","CERO","BK4112","NDAQ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4585","LU2210149790.SGD","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","BK4588"],"gpt_icon":1},{"id":"2544974589","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2544974589","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544974589?lang=en_us&edition=fundamental","pubTime":"2025-06-18 19:45","pubTimestamp":1750247114,"startTime":"0","endTime":"0","summary":"CERo Therapeutics  shares were 27% lower pre-bell Wednesday, paring Tuesday's rally.Borealis Foods  stock was down 22% following a 6.6% increase in the previous session.Eyenovia  shares were 16% lower, shaving gains from the previous session.Regencell Bioscience  stock was down 12% after a 30% increase on Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BRLS","CERO","BK4212","BK4139","EYEN","BK4007"],"gpt_icon":0},{"id":"2544399294","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2544399294","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544399294?lang=en_us&edition=fundamental","pubTime":"2025-06-18 02:14","pubTimestamp":1750184079,"startTime":"0","endTime":"0","summary":"CERo Therapeutics  said Tuesday that the US Food and Drug Administration has granted orphan drug designation for its lead drug candidate, CER-1236, for acute myeloid leukemia.Shares jumped over 220% as intraday trading volume advanced to over 51.2 million from a daily average of about 101,000.Acurx Pharmaceuticals  said its lead antibiotic candidate, ibezapolstat, is ready to advance to international phase 3 clinical trials to treat patients with C. difficile infection.Shares soared over 130% as intraday trading volume surged to more than 309 million from a daily average of roughly 182,000.Eli Lilly  said that it agreed to acquire Verve Therapeutics  for up to about $1.3 billion to advance gene-editing therapies for cardiovascular disease.Verve shares soared 78%, with intraday trading volume of more than 72.5 million against a daily average of about 3.49 million.Price: 22.04, Change: +15.18, Percent Change: +220.97","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0009355771.USD","SG9999014906.USD","LU0385154629.USD","LU1974910355.USD","LU0320765059.SGD","LU1093756168.USD","LU1232071149.USD","IE00BJT1NW94.SGD","LU0061475181.USD","GB00BDT5M118.USD","LU0354030438.USD","LU0354030511.USD","LU2491050154.USD","LU2112291526.USD","LU0106261372.USD","LU0234572021.USD","LU2552382215.SGD","SG9999015945.SGD","SG9999015986.USD","LU0097036916.USD","LU2361045086.USD","BK4563","LU0820561818.USD","SG9999018857.SGD","LU2468319806.SGD","LU1366192091.USD","LU0417517546.SGD","LU2602419157.SGD","LU1917777945.USD","CERO","BK4588","LU1291159041.SGD","LU1023059063.AUD","LU2237438978.USD","IE00BK4W5L77.USD","BK4007","LU2237443978.SGD","SGXZ81514606.USD","LU0058720904.USD","LU0320765992.SGD","LU1720051108.HKD","SGXZ51526630.SGD","BK4516","LU0786609619.USD","ACXP","LU0889565916.HKD","LU0471298777.SGD","LU0456855351.SGD"],"gpt_icon":1},{"id":"2544962193","title":"Cero Therapeutics Holdings Inc. Receives FDA Orphan Drug Designation for CER-1236 in Acute Myeloid Leukemia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2544962193","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544962193?lang=en_us&edition=fundamental","pubTime":"2025-06-17 20:15","pubTimestamp":1750162513,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc.  announced that the U.S. Food and Drug Administration  has granted Orphan Drug Designation  to its lead drug candidate, CER-1236, for the treatment of acute myeloid leukemia . This designation highlights the significance of developing innovative treatments for conditions affecting fewer than 200,000 patients in the U.S. annually. CER-1236, currently in Phase 1 clinical trials, utilizes engineered T cell therapeutics that incorporate phagocytic mechanisms. The ODD status provides Cero with several incentives, including FDA assistance in trial design, access to the FDA Orphan Drug Grants Program, exemption from the drug approval application fee, and eligibility for seven years of marketing exclusivity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL8zmcwF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2095319765.USD","BK4112","BK4588","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","BK4139","LU2210150020.SGD","CERO","LU2210149790.SGD"],"gpt_icon":0},{"id":"2543589456","title":"Cero Therapeutics Receives Nasdaq Delisting Notice Due to Bid Price Non-Compliance; Implements Reverse Stock Split to Address Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2543589456","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543589456?lang=en_us&edition=fundamental","pubTime":"2025-06-14 05:14","pubTimestamp":1749849295,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Receives Nasdaq Delisting Notice Due to Bid Price Non-Compliance; Implements Reverse Stock Split to Address Issue. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL3J2T2m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2542658278","title":"Cero Therapeutics Announces 1-for-20 Reverse Stock Split Effective June 13, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2542658278","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542658278?lang=en_us&edition=fundamental","pubTime":"2025-06-11 21:10","pubTimestamp":1749647408,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc.  announced a one-for-twenty reverse stock split of its common stock, effective June 13, 2025. As a result, the number of outstanding shares will be reduced from approximately 10.3 million to about 516,092. The stock will trade on a split-adjusted basis on the Nasdaq Capital Market. Proportional adjustments will also be made to equity incentive plans, stock options, preferred stock, and warrants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on June 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL7lbSgH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","BK4112","IE00BKPKM429.USD","CERO","LU2095319765.USD","NDAQ","LU2210149790.SGD","IE00B64PRP62.GBP","BK4139","IE00BGHQF748.EUR","BK4588","LU2210150020.SGD"],"gpt_icon":0},{"id":"2541361857","title":"Cero Therapeutics Holdings Inc. Announces Exercise of Option for Additional Series D Financing to Support Clinical Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2541361857","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541361857?lang=en_us&edition=fundamental","pubTime":"2025-06-06 20:15","pubTimestamp":1749212114,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. Announces Exercise of Option for Additional Series D Financing to Support Clinical Advancements. Cero Therapeutics Holdings Inc. has announced the exercise of an option for additional Series D financing. The company issued more shares of its Series D Preferred Stock to institutional investors, generating approximately $750,000 in gross proceeds. This funding will support the advancement of their clinical programs, including the recent FDA IND allowances in liquid and solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on June 06, 2025, and is solely responsible for the information c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL6DMj0v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","BK4588","LU2095319765.USD","IE00B3QW5Z07.USD","BK4585","IE00BGHQF748.EUR","LU2210149790.SGD","BK4112","IE00B64PRP62.GBP","LU2210150020.SGD","BK4139","CERO"],"gpt_icon":0},{"id":"2540713988","title":"Cero Therapeutics Holdings Inc. Appoints Chris Ehrlich as New CEO with Revised Employment Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2540713988","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540713988?lang=en_us&edition=fundamental","pubTime":"2025-06-03 04:22","pubTimestamp":1748895760,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. has announced a management change, appointing Chris Ehrlich as the new Chief Executive Officer effective June 4, 2025. This appointment follows the termination of his previous consulting agreement, expanding his role to a full-time position with the company. Ehrlich's leadership will be integral as Cero Therapeutics moves forward.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDLc1hcH4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0},{"id":"2540479342","title":"Cero Therapeutics Holdings Inc. Expands IP Portfolio with New U.S. and European Patent Approvals for Lead Compound CER-1236","url":"https://stock-news.laohu8.com/highlight/detail?id=2540479342","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540479342?lang=en_us&edition=fundamental","pubTime":"2025-06-02 21:05","pubTimestamp":1748869517,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. has announced a significant expansion of its intellectual property portfolio with the granting of two U.S. patents and the allowance of a European patent application. These developments pertain to the company's lead compound, CER-1236, and contribute to a total of 18 issued patents and allowed applications internationally, encompassing nine patent families. The newly granted U.S. Patent No. 12,303,551, titled \"CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,\" covers combination therapies involving CER-1236 for cancer treatment. The company's intellectual property now has protection extending to 2042 in the United States.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL8L8lVs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","NDAQ","CERO","BK4139","LU2095319765.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4588","BK4112"],"gpt_icon":0},{"id":"2539422755","title":"BRIEF-CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2539422755","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539422755?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:52","pubTimestamp":1748609544,"startTime":"0","endTime":"0","summary":"BRIEF-CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical TrialMay 30 (Reuters) - CERo Therapeutics Holdings Inc CERO.O:CERO THERAPEUTICS HOLDINGS, INC. DOSES FIRST ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUA3KVDL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CERO","BK4139"],"gpt_icon":0},{"id":"2539222122","title":"CERo Therapeutics Cut to Hold From Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2539222122","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539222122?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:35","pubTimestamp":1748608500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CERO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 30, 2025 08:35 ET (12:35 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","LENZ","CERO","BK4539"],"gpt_icon":0},{"id":"2539296700","title":"Cero Therapeutics Holdings Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2539296700","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539296700?lang=en_us&edition=fundamental","pubTime":"2025-05-30 05:11","pubTimestamp":1748553064,"startTime":"0","endTime":"0","summary":"Cero Therapeutics Holdings Inc. held its 2025 Annual Meeting of Stockholders on May 29, 2025. Stockholders approved an amendment to increase the number of shares available under the 2024 Equity Incentive Plan by an additional 2,000,000 shares. Additionally, the issuance of shares of Common Stock in accordance with Nasdaq Listing Rule 5635, upon the exercise of warrants issued in a registered direct offering in February 2025, was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2025, and is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDLkq2RJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CERO"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":45,"code":"91000000","status":"200"}]}}